Pharmaceutical News

RSS

ProStrakan, Orexo reconfigure commercial rights to Abstral

Orexo AB and ProStrakan Group plc jointly announce today that the companies have reconfigured the commercial rights to the product, Abstral, in various territories worldwide.

4 Jun 2012

Prisoners need education on the appropriate use of topical antibiotic products

Prisoners need education on the appropriate use of topical antibiotic products, according to a study released today at the 39th Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

4 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

New research: Foggers ineffective against bed bugs

Consumer products known as "bug bombs" or "foggers" have been sold for decades for use against many common household insects. However, recent research published in the Journal of Economic Entomology (JEE) shows these products to be ineffective against bed bugs.

4 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Global generic pharmaceuticals market to reach $231.00 billion in 2017 at 9.29% CAGR

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide.

2 Jun 2012

Cera announces new citrus ready-to-drink oral rehydration solution

Cera Products is proud to announce its new CeraLyte-70 Citrus Ready to Drink in a 500 ml environmentally green container with a re-closeable top and a long shelf-life. No mixing is needed, saving health care staff time when fast patient hydration is needed.

2 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

HIV markets in rich, poor countries are two distinct markets

HIV drugs have not only "transformed a fatal disease into a chronic one," but "[t]hey have also made HIV a big business," this Economist editorial states.

2 Jun 2012

Study provides novel mechanism of action of anti-cancer compound: perifosine

Aeterna Zentaris Inc. today announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma (MMe), an aggressive type of cancer associated with exposure to asbestos.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Scientists discover previously unrecognized signaling network disrupted in lung cancer

A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs.

2 Jun 2012

Increased risk of bladder cancer linked to diabetes drug

Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.

1 Jun 2012

Feds announce effort to slash inappropriate use of antipsychotic drugs in nursing homes

An estimated 40 percent of nursing home residents with dementia receive the drugs, which are approved to treat schizophrenia and bipolar disorder.

1 Jun 2012

KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."

1 Jun 2012

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry on the anti-tumor activity of its RX-3117 compound.

1 Jun 2012

Seriously ill children administered zinc in addition to antibiotics respond better, more quickly to treatment, study shows

"In a newly released clinical study, conducted in India" and published in the Lancet on Thursday, "hundreds of seriously ill infants who received zinc -- an essential micronutrient for the immune system and human growth -- as well as antibiotics, responded better and more quickly to treatment than those who did not," IRIN reports.

1 Jun 2012

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

1 Jun 2012

Vitamin D3 supplements could provide more health benefits

New research funded by the Biotechnology and Biological Sciences Research Council (BBSRC) has shown that vitamin D3 supplements could provide more benefit than the close relative vitamin D2.

1 Jun 2012